Spectrin beta 3 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28988
Key Product Details
Species Reactivity
Human
Applications
Immunoprecipitation, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
between 2340 and 2390
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for Spectrin beta 3 Antibody
Application
Recommended Usage
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
Tris-buffered Saline 0.1% BSA
Preservative
0.09% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: beta-III Spectrin
Mutations in this gene cause a form of spinocerebellar ataxia, SCA5, that is characterized by neurodegeneration, progressive locomotor incoordination, dysarthria, and uncoordinated eye movements. Mutations in spectrins are a previously unknown cause of ataxia and neurodegenerative disease that affect membrane proteins involved in glutamate signaling. Spectrin-beta IIIs have been recognized as ataxia disease genes and their mutations cause spinocerebellar ataxia type 5 (SCA5).
Long Name
Spectrin Beta, Non-Erythrocytic 2
Alternate Names
GTRAP41, SCA5, SCAR14, Spectrin beta 3, Spectrin beta III, SPTBN2
Gene Symbol
SPTBN2
Additional beta-III Spectrin Products
Product Specific Notices for Spectrin beta 3 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...